



(51) International Patent Classification:
C07K 16/24 (2006.01)

(21) International Application Number:
PCT/IB2024/061799

(22) International Filing Date:
25 November 2024 (25.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/602,704 27 November 2023 (27.11.2023) US

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL
PROPERTY DEVELOPMENT LIMITED** [GB/GB];
GSK Medicines Research Centre, Gunnels Wood Road,
Stevenage SG1 2NY (GB).

(72) Inventors: **ORECCHIA, Martin**; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **EDWARDS, Matthew**; c/o GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **BEATON, Andrew**; c/o GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **HOOK, Laura**; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage Hertfordshire SG12NY (GB). **DIXON, David**; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **GUO, Xieyang**; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **CHUNG, Chun-wa**; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: IL-33 BINDING ANTIBODIES

concentration effect of 22A06-458 on IL-33 stimulated
eosinophil superoxide generation




Figure 1

(57) Abstract: The present disclosure relates to the treatment of interleukin 33 (IL-33) mediated diseases, including lung diseases. In particular, the present disclosure relates to IL-33 binding proteins, including anti-IL-33 antibodies, and their uses in the treatment of IL-33 mediated diseases.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*